HFJV under general anesthesia as safe as spontaneous respiration under moderate sedation for percutaneous lung ablation
Increased radiation with SABR boost seems to enhance local control but with reduced overall survival at highest dose
Intensity-modulated radiation therapy spares more normal tissue than 3D-conformal radiotherapy
Findings seen compared with stereotactic body radiotherapy for early-stage disease
Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites
At three, six, and nine years, overall survival was 64, 43, and 26 percent and progression-free survival was 88, 78, and 78 percent, respectively
Survival outcomes for SCLC patients with brain metastases appear to be equitable with stereotactic radiosurgery, whole brain radiotherapy